Anti-Xa activity after enoxaparin prophylaxis in hospitalized patients weighing less than fifty-five kilograms.

摘要: Abstract Introduction Low-molecular-weight heparins are commonly used for the prophylaxis of thromboembolic disease. In contrast to therapeutic doses, recommended prophylactic doses fixed (i.e., 40 mg/day enoxaparin). Dosing patients with extreme body weights has not been well studied, especially dosing low weight patients. Objectives To establish anti-Xa activity that results from enoxaparin in inpatients ≤ 55 kg. Patients/Methods Cross-sectional study including older than 18 years, ≤ 55 kg, and whose treating physician found indication enoxaparin. We excluded renal failure those using oral anticoagulants. Anti-Xa was measured 3 hours after second dose Statistical analyses were conducted determine effect on levels. Results Average age 72.5 years (interquartile range, 30) median 49.7 kg 7). Twenty-five percent weighed ≤ 45 kg, 37.5% 46–50 kg, 51–55 kg. The mean 0.54 ± 0.18 IU/ml, 60% exhibited ≥ 0.5 IU/ml. Weight inversely correlated (Spearman’s rho = − 0.428, p = 0.001). Patients weighing ≤ 45 kg higher (0.61 ± 0.18 IU/ml, p = 0.008) heavier an odds ratio 8 level ≥ 0.5 IU/ml (95% CI: 1.42-45.06). Conclusions Anti-factor Xa rises significantly when decreases. weight,